Background: Galectin-9 (Gal-9) is a member of the growing family of β-galactoside-binding lectins. Gal-9 is an eosinophil chemoattractant and inducer of Th1 cell apoptosis. These effects suggest its potential role in the pathogenesis of asthma. Our aim was to study the expression of Gal-9 in an ovalbumin (OVA)-induced mouse model of allergic asthma. Methods: To investigate the significance of Gal-9 in allergic inflammation and airway hyperresponsiveness (AHR), a group of BALB/c mice was sensitized and challenged with OVA (GOVA). Another group of animals was allergized with OVA and also treated with dexamethasone (DEX) (GOVA+DEX). The control group (GPBS) received phosphate-buffered saline instead of OVA as placebo. Airway reactivity to intravenous methacholine was assessed. Results: The percentage of Gal-9-positive cells and their intracellular Gal-9 content and Th1/Th2 cytokine levels in the bronchoalveolar lavage (BAL) were determined by flow cytometry. Gal-9 mRNA expression and protein level were measured in the lung tissue by real-time RT-PCR and Western blot. In GOVA mice, airway inflammation and mucus hypersecretion developed. DEX treatment inhibited the main features of experimental asthma. The number of Gal-9-positive lymphocytes, eosinophil and neutrophil granulocytes and the levels of Th2 cytokines were higher in the BAL of GOVA compared to GPBS or GOVA+DEX mice. Moreover, Gal-9 protein level was elevated in the lungs of GOVA mice. Conclusions: These results suggest that Gal-9 plays a role as a mediator contributing to the development of allergic airway inflammation. Gal-9 may serve as a recruiter of eosinophil granulocytes and promoter of Th2 dominance.

Keywords:
Galectin-9, Asthma, Eosinophils, Allergic inflammation, Animal model
1.
Busse WW, Lemanske RF Jr: Expert Panel Report 3: Moving forward to improve asthma care. J Allergy Clin Immunol 2007;120:1012–1014.
2.
McFadden ER Jr, Gilbert IA: Asthma. N Engl J Med 1992;327:1928–1937.
3.
Beasley R, Roche WR, Roberts JA, Holgate ST: Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis 1989;139:806–817.
4.
Robinson DS: The role of the mast cell in asthma: induction of airway hyperresponsiveness by interaction with smooth muscle? J Allergy Clin Immunol 2004;114:58–65.
5.
Cohn L, Elias JA, Chupp GL: Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol 2004;22:789–815.
6.
Kay AB, Barata L, Meng Q, Durham SR, Ying S: Eosinophils and eosinophil-associated cytokines in allergic inflammation. Int Arch Allergy Immunol 1997;113:196–199.
7.
Bischof RJ, Meeusen EN: Cellular kinetics of an allergic-type response in a sheep mammary gland model of inflammation. Clin Exp Allergy 2002;32:619–626.
8.
Hirabayashi J, Kasai K: The family of metazoan metal-independent β-galactoside-binding lectins: structure, function and molecular evolution. Glycobiology 1993;3:297–304.
9.
Barondes SH, Cooper DN, Gitt MA, Leffler H: Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994;269:20807–20810.
10.
Caron M, Bladier D, Joubert R: Soluble galactoside-binding vertebrate lectins: a protein family with common properties. Int J Biochem 1990;22:1379–1385.
11.
Yamaoka A, Kuwabara I, Frigeri LG, Liu FT: A human lectin, galectin-3 (ε bp/Mac-2), stimulates superoxide production by neutrophils. J Immunol 1995;154:3479–3487.
12.
Levi G, Tarrab-Hazdai R, Teichberg VI: Prevention and therapy with electrolectin of experimental autoimmune myasthenia gravis in rabbits. Eur J Immunol 1983;13:500–507.
13.
Offner H, Celnik B, Bringman TS, Casentini-Borocz D, Nedwin GE, Vandenbark AA: Recombinant human β-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis. J Neuroimmunol 1990;28:177–184.
14.
Van den Brûle FA, Buicu C, Baldet M, Sobel ME, Cooper DN, Marschal P, Castronovo V: Galectin-1 modulates human melanoma cell adhesion to laminin. Biochem Biophys Res Commun 1995;209:760–767.
15.
Wells V, Mallucci L: Identification of an autocrine negative growth factor: mouse β-galactoside-binding protein is a cytostatic factor and cell growth regulator. Cell 1991;64:91–97.
16.
Adams L, Scott GK, Weinberg CS: Biphasic modulation of cell growth by recombinant human galectin-1. Biochim Biophys Acta 1996;1312:137–144.
17.
Perillo NL, Pace KE, Seilhamer JJ, Baum LG: Apoptosis of T cells mediated by galectin-1. Nature 1995;378:736–739.
18.
Yang RY, Hsu DK, Liu FT: Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 1996;93:6737–6742.
19.
Rabinovich GA: Galectins: an evolutionarily conserved family of animal lectins with multifunctional properties; a trip from the gene to clinical therapy. Cell Death Differ 1999;6:711–721.
20.
Almkvist J, Karlsson A: Galectins as inflammatory mediators. Glycoconj J 2004;19:575–581.
21.
Türeci O, Schmitt H, Fadle N, Pfreundschuh M, Sahin U: Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin’s disease. J Biol Chem 1997;272:6416–6422.
22.
Wada J, Kanwar YS: Identification and characterization of galectin-9, a novel β-galactoside-binding mammalian lectin. J Biol Chem 1997;272:6078–6086.
23.
Matsumoto R, Matsumoto H, Seki M, Hata M, Asano Y, Kanegasaki S, Stevens RL, Hirashima M: Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem 1998;273:16976–16984.
24.
Lipkowitz MS, Leal-Pinto E, Rappoport JZ, Najfeld V, Abramson RG: Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter. J Clin Invest 2001;107:1103–1115.
25.
Wada J, Ota K, Kumar A, Wallner EI, Kanwar YS: Developmental regulation, expression, and apoptotic potential of galectin-9, a β-galactoside binding lectin. J Clin Invest 1997;99:2452–2461.
26.
Saita N, Goto E, Yamamoto T, Cho I, Tsumori K, Kohrogi H, Maruo K, Ono T, Takeya M, Kashio Y, Nakamura K, Hirashima M: Association of galectin-9 with eosinophil apoptosis. Int Arch Allergy Immunol 2002;128:42–50.
27.
Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK: The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005;6:1245–1252.
28.
Yamamoto H, Kashio Y, Shoji H, Shinonaga R, Yoshimura T, Nishi N, Nabe T, Nakamura T, Kohno S, Hirashima M: Involvement of galectin-9 in guinea pig allergic airway inflammation. Int Arch Allergy Immunol 2007;143:95–105.
29.
Kozma GT, Losonczy G, Keszei M, Komlósi Z, Buzás E, Pállinger E, Appel J, Szabó T, Magyar P, Falus A, Szalai C: Histamine deficiency in gene-targeted mice strongly reduces antigen-induced airway hyper-responsiveness, eosinophilia and allergen-specific IgE. Int Immunol 2003;15:963–973.
30.
Meyuhas O, Baldin V, Bouche G, Amalric F: Glucocorticoids repress ribosome biosynthesis in lymphosarcoma cells by affecting gene expression at the level of transcription, posttranscription and translation. Biochim Biophys Acta 1990;1049:38–44.
31.
Kumagai K, Ohno I, Imai K, Nawata J, Hayashi K, Okada S, Senoo H, Hattori T, Shirato K: The involvement of matrix metalloproteinases in basement membrane injury in a murine model of acute allergic airway inflammation. Clin Exp Allergy 2002;32:1527–1534.
32.
Komlósi ZI, Pozsonyi E, Tábi T, Szöko E, Nagy A, Bartos B, Kozma GT, Tamási L, Orosz M, Magyar P, Losonczy G: Lipopolysaccharide exposure makes allergic airway inflammation and hyper-responsiveness less responsive to dexamethasone and inhibition of iNOS. Clin Exp Allergy 2006;36:951–959.
33.
Glaab T, Taube C, Braun A, Mitzner W: Invasive and noninvasive methods for studying pulmonary function in mice. Respir Res 2007;8:63.
34.
Peebles RS Jr, Dworski R, Collins RD, Jarzecka K, Mitchell DB, Graham BS, Sheller JR: Cyclooxygenase inhibition increases interleukin 5 and interleukin 13 production and airway hyperresponsiveness in allergic mice. Am J Respir Crit Care Med 2000;162:676–681.
35.
Kay AB: Asthma and inflammation. J Allergy Clin Immunol 1991;87:893–910.
36.
Dunphy JL, Barcham GJ, Bischof RJ, Young AR, Nash A, Meeusen EN: Isolation and characterization of a novel eosinophil-specific galectin released into the lungs in response to allergen challenge. J Biol Chem 2002;277:14916–14924.
37.
Breuilh L, Vanhoutte F, Fontaine J, van Stijn CM, Tillie-Leblond I, Capron M, Faveeuw C, Jouault T, van Die I, Gosset P, Trottein F: Galectin-3 modulates immune and inflammatory responses during helminthic infection: impact of galectin-3 deficiency on the functions of dendritic cells. Infect Immun 2007;75:5148–5157.
38.
Bernardes ES, Silva NM, Ruas LP, Mineo JR, Loyola AM, Hsu DK, Liu FT, Chammas R, Roque-Barreira MC: Toxoplasma gondii infection reveals a novel regulatory role for galectin-3 in the interface of innate and adaptive immunity. Am J Pathol 2006;168:1910–1920.
39.
Epstein MM: Are mouse models of allergic asthma useful for testing novel therapeutics? Exp Toxicol Pathol 2006;57:41–44.
40.
Hirashima M: Ecalectin/galectin-9, a novel eosinophil chemoattractant: its function and production. Int Arch Allergy Immunol 2000;122:6–9.
41.
Christodoulopoulos P, Cameron L, Nakamura Y, Lemière C, Muro S, Dugas M, Boulet LP, Laviolette M, Olivenstein R, Hamid Q: Th2 cytokine-associated transcription factors in atopic and nonatopic asthma: evidence for differential signal transducer and activator of transcription 6 expression. J Allergy Clin Immunol 2001;107:586–591.
42.
Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB: Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298–304.
43.
Asakura H, Kashio Y, Nakamura K, Seki M, Dai S, Shirato Y, Abedin MJ, Yoshida N, Nishi N, Imaizumi T, Saita N, Toyama Y, Takashima H, Nakamura T, Ohkawa M, Hirashima M: Selective eosinophil adhesion to fibroblast via IFN-γ-induced galectin-9. J Immunol 2002;169:5912–5918.
44.
Katoh S, Ishii N, Nobumoto A, Takeshita K, Dai SY, Shinonaga R, Niki T, Nishi N, Tominaga A, Yamauchi A, Hirashima M: Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. Am J Respir Crit Care Med 2007;176:27–35.
45.
Inoue H, Fukuyama S, Matsumoto K, Kubo M, Yoshimura A: Role of endogenous inhibitors of cytokine signaling in allergic asthma. Curr Med Chem 2007;14:181–189.
46.
Hogan SP: Recent advances in eosinophil biology. Int Arch Allergy Immunol 2007;143:3–14.
47.
Thomas LH, Warner JA: The eosinophil and its role in asthma. Gen Pharmacol 1996;27:593–597.
48.
Ohashi Y, Motojima S, Fukuda T, Makino S: Airway hyperresponsiveness, increased intracellular spaces of bronchial epithelium, and increased infiltration of eosinophils and lymphocytes in bronchial mucosa in asthma. Am Rev Respir Dis 1992;145:1469–1476.
49.
Weller PF: The immunobiology of eosinophils. N Engl J Med 1991;324:1110–1118.
50.
Wills-Karp M: Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol 1999;17:255–281.
51.
Hamelmann E, Gelfand EW: IL-5-induced airway eosinophilia – the key to asthma? Immunol Rev 2001;179:182–191.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.